Thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, are Peroxisome proliferator-activated receptor gamma (PPARγ) agonists initially used to control blood glucose levels in type 2 diabetes but have shown complex effects in AMD. This evidence concerns the gene PPARG and age-related macular degeneration.